<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03245008</url>
  </required_header>
  <id_info>
    <org_study_id>MT-5547-J01</org_study_id>
    <nct_id>NCT03245008</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain</brief_title>
  <official_title>A Phase 2/3 (Placebo-Controlled, Double-Blind, Comparative) Study on MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to verify the superiority of 16 weeks of MT-5547 treatment to&#xD;
      placebo, as evidenced by the WOMAC pain score (the efficacy outcome measure), in patients&#xD;
      with osteoarthritis of the knee or hip. Additional objectives of the study are to investigate&#xD;
      the efficacy, safety, and pharmacokinetics of MT-5547 in long-term use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The blind will be maintained, including for the study sponsor, until the key code is opened&#xD;
      after the data have been fixed for all subjects in Week 24. In addition, in order to&#xD;
      eliminate any bias that could affect the study assessments, to the extent possible, the blind&#xD;
      will be maintained with respect to the study site and the subject even after the opening of&#xD;
      the study sponsor key code.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2017</start_date>
  <completion_date type="Actual">March 9, 2021</completion_date>
  <primary_completion_date type="Actual">December 14, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC pain score (change from baseline at Week 16)</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PGA) (change from baseline at each assessment time point)</measure>
    <time_frame>Baseline to Week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC pain score (change from baseline at each assessment time point)</measure>
    <time_frame>Baseline to Week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC physical function score (change from baseline at each assessment time point)</measure>
    <time_frame>Baseline to Week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC stiffness score (change from baseline at each assessment time point)</measure>
    <time_frame>Baseline to Week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC total score (change from baseline at each assessment time point)</measure>
    <time_frame>Baseline to Week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and adverse drug reactions</measure>
    <time_frame>Baseline to Week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessments if a Joint Replacement Procedure Is Scheduled</measure>
    <time_frame>Baseline to Week 68</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">626</enrollment>
  <condition>Osteoarthritis, Knee / Osteoarthritis, Hip</condition>
  <arm_group>
    <arm_group_label>MT-5547 dosing regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-5547 Subcutaneous (SC) dosing regimen 1. Naproxen-matching placebo oral after Week 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-5547 dosing regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-5547 SC dosing regimen 2. Naproxen-matching placebo oral after Week 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-5547-matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MT-5547-matching placebo SC dosing. Naproxen oral after Week 16.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-5547</intervention_name>
    <description>Solution for injection in pre-filled syringe</description>
    <arm_group_label>MT-5547 dosing regimen 1</arm_group_label>
    <arm_group_label>MT-5547 dosing regimen 2</arm_group_label>
    <other_name>Fasinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-5547-matching placebo</intervention_name>
    <description>Solution for injection in pre-filled syringe</description>
    <arm_group_label>MT-5547 dosing regimen 2</arm_group_label>
    <arm_group_label>MT-5547-matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Additional screening criteria check may apply for qualification:&#xD;
&#xD;
          -  Male and female Japanese patients, 40 years to 85 years at the time written informed&#xD;
             consent is obtained.&#xD;
&#xD;
          -  Patients who have been diagnosed with osteoarthritis (OA) of the knee or hip based on&#xD;
             the American College of Rheumatology (ACR) criteria.&#xD;
&#xD;
          -  Patients with an evaluated joint (knee or hip) with a K-L (Kellgren-Lawrence) score of&#xD;
             ≥2 based on the X-ray test performed.&#xD;
&#xD;
          -  Moderate to severe pain in the evaluated joint, defined as a WOMAC pain score of ≥4&#xD;
             (mean of the 5 items), on the WOMAC assessments.&#xD;
&#xD;
          -  Patients who satisfy both 1) and 2) below.&#xD;
&#xD;
               1. Inadequate OA pain relief from at least 1 oral NSAID.&#xD;
&#xD;
               2. Intolerance to or inadequate OA pain relief from at least 1 opioid (including&#xD;
                  combination drugs), or unwillingness to take opioid therapy.&#xD;
&#xD;
          -  Patients who agree to not change their current lifestyle (daily living activities and&#xD;
             exercise) throughout the study.&#xD;
&#xD;
          -  Patients who are able to complete post-operative follow-up for any joint replacement&#xD;
             surgery that is performed during the study.&#xD;
&#xD;
          -  Body mass index at screening ≤39.&#xD;
&#xD;
          -  Patient who are able to understand and answer endpoint questions used in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Additional screening criteria check may apply for qualification:&#xD;
&#xD;
          -  Presence of symptoms of carpal tunnel syndrome within 6 months before screening.&#xD;
&#xD;
          -  Patients who cannot undergo MRI.&#xD;
&#xD;
          -  Trauma to the index joint within 3 months prior to screening.&#xD;
&#xD;
          -  Presence or history of inflammatory joint diseases other than OA, Paget's disease of&#xD;
             the spine, pelvis or femur, multiple sclerosis, fibromyalgia, vertebral tumors or&#xD;
             infections, or renal osteodystrophy.&#xD;
&#xD;
          -  Presence or history, confirmed by imaging, of arthropathy, neuropathic joint&#xD;
             arthropathy, hip dislocation, knee dislocation, extensive subchondral cyst, marked&#xD;
             bone destruction or bone loss, or pathologic fractures.&#xD;
&#xD;
          -  Autonomic neuropathy diagnosed in the assessment of autonomic nerve symptoms performed&#xD;
             at screening, or baseline.&#xD;
&#xD;
          -  Presence or history of orthostatic hypotension at the orthostatic hypotension&#xD;
             assessments performed at screening, prerandomization, or baseline.&#xD;
&#xD;
          -  Presence or history of autonomic neuropathy, diabetic neuropathy, or other peripheral&#xD;
             neuropathy such as reflex sympathetic dystrophy at screening.&#xD;
&#xD;
          -  Presence or history of chronic familial dysautonomia.&#xD;
&#xD;
          -  Intolerance to naproxen.&#xD;
&#xD;
          -  Systemic (excluding topical, intranasal, ophthalmic, and inhaled formulations)&#xD;
             corticosteroids within 4 weeks prior to screening.&#xD;
&#xD;
          -  Intra-articular corticosteroids in the evaluated joint within 12 weeks prior to&#xD;
             screening, or in any other joint within 4 weeks prior to screening.&#xD;
&#xD;
          -  Received an intra-articular injection of hyaluronic acid in any joint within the&#xD;
             period specified for each medicine prior to screening.&#xD;
&#xD;
          -  Resting heart rate of &lt;50 bpm or &gt;100 bpm at screening, or baseline.&#xD;
&#xD;
          -  Presence or history of 2nd or 3rd degree heart block, 1st degree heart block with&#xD;
             abnormal QRS, or bifascicular block by ECG assessment at screening.&#xD;
&#xD;
          -  Non-compliance with the Numerical rating scale (NRS) recording (average pain on&#xD;
             walking in the evaluated joint over 1 day) during the pre-treatment observation&#xD;
             period.&#xD;
&#xD;
          -  Women who are pregnant, breast-feeding, or may be pregnant.&#xD;
&#xD;
          -  Use of an anti-Nerve growth factor (anti-NGF) antibody in the past, or apparent&#xD;
             hypersensitivity or intolerance to anti-NGF antibodies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Mie</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasinumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

